PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
GERN vs. VKTX
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between GERN and VKTX is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

GERN vs. VKTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Geron Corporation (GERN) and Viking Therapeutics, Inc. (VKTX). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%OctoberNovemberDecember2025FebruaryMarch
-53.54%
229.80%
GERN
VKTX

Key characteristics

Sharpe Ratio

GERN:

-0.15

VKTX:

-0.81

Sortino Ratio

GERN:

0.59

VKTX:

-1.33

Omega Ratio

GERN:

1.08

VKTX:

0.84

Calmar Ratio

GERN:

-0.18

VKTX:

-0.94

Martin Ratio

GERN:

-0.73

VKTX:

-1.67

Ulcer Index

GERN:

23.80%

VKTX:

41.01%

Daily Std Dev

GERN:

112.18%

VKTX:

84.86%

Max Drawdown

GERN:

-98.65%

VKTX:

-90.41%

Current Drawdown

GERN:

-97.39%

VKTX:

-69.65%

Fundamentals

Market Cap

GERN:

$1.10B

VKTX:

$3.22B

EPS

GERN:

-$0.27

VKTX:

-$1.01

PEG Ratio

GERN:

-2.38

VKTX:

-0.03

Total Revenue (TTM)

GERN:

$76.99M

VKTX:

$0.00

Gross Profit (TTM)

GERN:

$75.43M

VKTX:

-$236.00K

EBITDA (TTM)

GERN:

-$154.85M

VKTX:

-$150.74M

Returns By Period

In the year-to-date period, GERN achieves a -51.41% return, which is significantly lower than VKTX's -28.73% return.


GERN

YTD

-51.41%

1M

-40.89%

6M

-59.81%

1Y

-18.10%

5Y*

11.05%

10Y*

-7.29%

VKTX

YTD

-28.73%

1M

-11.40%

6M

-48.22%

1Y

-68.55%

5Y*

37.81%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

GERN vs. VKTX — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GERN
The Risk-Adjusted Performance Rank of GERN is 4444
Overall Rank
The Sharpe Ratio Rank of GERN is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of GERN is 5252
Sortino Ratio Rank
The Omega Ratio Rank of GERN is 5252
Omega Ratio Rank
The Calmar Ratio Rank of GERN is 3939
Calmar Ratio Rank
The Martin Ratio Rank of GERN is 3434
Martin Ratio Rank

VKTX
The Risk-Adjusted Performance Rank of VKTX is 66
Overall Rank
The Sharpe Ratio Rank of VKTX is 99
Sharpe Ratio Rank
The Sortino Ratio Rank of VKTX is 88
Sortino Ratio Rank
The Omega Ratio Rank of VKTX is 99
Omega Ratio Rank
The Calmar Ratio Rank of VKTX is 22
Calmar Ratio Rank
The Martin Ratio Rank of VKTX is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

GERN vs. VKTX - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and Viking Therapeutics, Inc. (VKTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for GERN, currently valued at -0.19, compared to the broader market-3.00-2.00-1.000.001.002.003.00-0.19-0.70
The chart of Sortino ratio for GERN, currently valued at 0.50, compared to the broader market-4.00-2.000.002.004.000.50-0.95
The chart of Omega ratio for GERN, currently valued at 1.07, compared to the broader market0.501.001.502.001.070.89
The chart of Calmar ratio for GERN, currently valued at -0.28, compared to the broader market0.001.002.003.004.005.00-0.28-0.81
The chart of Martin ratio for GERN, currently valued at -0.85, compared to the broader market0.005.0010.0015.0020.00-0.85-1.59
GERN
VKTX

The current GERN Sharpe Ratio is -0.15, which is higher than the VKTX Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of GERN and VKTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.004.005.00OctoberNovemberDecember2025FebruaryMarch
-0.19
-0.70
GERN
VKTX

Dividends

GERN vs. VKTX - Dividend Comparison

Neither GERN nor VKTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

GERN vs. VKTX - Drawdown Comparison

The maximum GERN drawdown since its inception was -98.65%, which is greater than VKTX's maximum drawdown of -90.41%. Use the drawdown chart below to compare losses from any high point for GERN and VKTX. For additional features, visit the drawdowns tool.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%OctoberNovemberDecember2025FebruaryMarch
-72.26%
-68.73%
GERN
VKTX

Volatility

GERN vs. VKTX - Volatility Comparison

Geron Corporation (GERN) has a higher volatility of 43.44% compared to Viking Therapeutics, Inc. (VKTX) at 29.59%. This indicates that GERN's price experiences larger fluctuations and is considered to be riskier than VKTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%OctoberNovemberDecember2025FebruaryMarch
43.44%
29.59%
GERN
VKTX

Financials

GERN vs. VKTX - Financials Comparison

This section allows you to compare key financial metrics between Geron Corporation and Viking Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab